NCT02732171View on ClinicalTrials.gov

PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer

NARecruitingINTERVENTIONAL
Enrollment

600

Participants

Timeline

Start Date

April 30, 2016

Primary Completion Date

April 30, 2028

Study Completion Date

April 30, 2030

Conditions
Breast Cancer
Interventions
OTHER

Research Blood Collection

Multiple tubes of research blood collected for biomarker analyses (circulating tumor material, immune profiling)

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER

NCT02732171 - PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer | Biotech Hunter | Biotech Hunter